These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23571389)

  • 1. Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes.
    Edwards CM
    Br J Hosp Med (Lond); 2013 Apr; 74(4):198-201. PubMed ID: 23571389
    [No Abstract]   [Full Text] [Related]  

  • 2. The clinical challenges of managing type 2 diabetes and the potential of GLP-1-based therapies.
    Zinman B
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():1-3. PubMed ID: 19878255
    [No Abstract]   [Full Text] [Related]  

  • 3. Albiglutide for the treatment of type 2 diabetes mellitus.
    McCarty DJ
    Nurse Pract; 2017 Feb; 42(2):10-11. PubMed ID: 28085780
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
    Unger J
    J Am Osteopath Assoc; 2011 Feb; 111(2 Suppl 1):eS2-9. PubMed ID: 21389296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis.
    Gargiulo P; Savarese G; D'Amore C; De Martino F; Lund LH; Marsico F; Dellegrottaglie S; Marciano C; Trimarco B; Perrone-Filardi P
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1081-1088. PubMed ID: 29113708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GLP-1 agonists: improving the future of patients with type 2 diabetes.
    Shubrook JH
    J Am Osteopath Assoc; 2011 Feb; 111(2 Suppl 1):2 p preceding eS2. PubMed ID: 21409846
    [No Abstract]   [Full Text] [Related]  

  • 7. Choosing among the incretin agents and why it matters.
    Unger J
    J Fam Pract; 2010 May; 59(5 Suppl):S30-5. PubMed ID: 20544056
    [No Abstract]   [Full Text] [Related]  

  • 8. [Glucagon-like peptide 1 analogues in the treatment of type 2 diabetes mellitus].
    Christensen M; Vilsbøll T; Knop FK
    Ugeskr Laeger; 2012 Aug; 174(34):1935; discussion 1935. PubMed ID: 23077741
    [No Abstract]   [Full Text] [Related]  

  • 9. Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes.
    Pratley RE
    J Am Acad Nurse Pract; 2008 Nov; 20 Suppl 1():7-11. PubMed ID: 19402254
    [No Abstract]   [Full Text] [Related]  

  • 10. Current challenges in type 2 diabetes.
    Garber AJ
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():1-3. PubMed ID: 22405263
    [No Abstract]   [Full Text] [Related]  

  • 11. Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage.
    Moses A
    BMJ; 2013 Jul; 347():f4386. PubMed ID: 23842435
    [No Abstract]   [Full Text] [Related]  

  • 12. Insulin treatment for type 2 diabetes: when to start, which to use.
    Hamaty M
    Cleve Clin J Med; 2011 May; 78(5):332-42. PubMed ID: 21536829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incretin therapy and its effect on body weight in patients with diabetes.
    Lind M
    Prim Care Diabetes; 2012 Oct; 6(3):187-91. PubMed ID: 22613745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New medications for patients with type 2 diabetes].
    Meillet L
    Soins; 2014 Oct; (789):15-8. PubMed ID: 25518129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Will Gut Microbiota Help Design the Next Generation of GLP-1-Based Therapies for Type 2 Diabetes?
    Claus SP
    Cell Metab; 2017 Jul; 26(1):6-7. PubMed ID: 28683295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Glucagon-like peptide 1 analogues in the treatment of type 2 diabetes mellitus].
    Beck-Nielsen H
    Ugeskr Laeger; 2012 Jun; 174(23):1606-8. PubMed ID: 22673382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy.
    Yoshida M; Asai M; Miyata M; Ogawa K; Maeda H; Oiso Y
    Diabetes Res Clin Pract; 2012 Jun; 96(3):e55-6. PubMed ID: 22257418
    [No Abstract]   [Full Text] [Related]  

  • 18. [The value of incretin based therapies].
    Gallwitz B
    Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
    [No Abstract]   [Full Text] [Related]  

  • 19. Harnessing the weight-regulating properties of glucagon-like peptide-1 in the treatment of type 2 diabetes.
    Sesti G
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():4-10. PubMed ID: 19878256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of incretin-based therapies in the management of type 2 diabetes.
    Bandyopadhyay P
    Drug News Perspect; 2009 Nov; 22(9):559-67. PubMed ID: 20072733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.